These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35468166)

  • 21. Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.
    Ayoub MA; See HB; Seeber RM; Armstrong SP; Pfleger KD
    PLoS One; 2013; 8(5):e64672. PubMed ID: 23700486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies.
    van der Horst EH; Murgia M; Treder M; Ullrich A
    Int J Cancer; 2005 Jul; 115(4):519-27. PubMed ID: 15704104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of HER3 in gastric cancer.
    Wang L; Yuan H; Li Y; Han Y
    Biomed Pharmacother; 2014 Jul; 68(6):809-12. PubMed ID: 25194439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas.
    Rysman B; Mouawad F; Gros A; Lansiaux A; Chevalier D; Meignan S
    Head Neck; 2016 Apr; 38 Suppl 1():E2412-8. PubMed ID: 26835877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a heregulin binding site in HER3 extracellular domain.
    Singer E; Landgraf R; Horan T; Slamon D; Eisenberg D
    J Biol Chem; 2001 Nov; 276(47):44266-74. PubMed ID: 11555649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation.
    Yudt MR; Vorojeikina D; Zhong L; Skafar DF; Sasson S; Gasiewicz TA; Notides AC
    Biochemistry; 1999 Oct; 38(43):14146-56. PubMed ID: 10571988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
    Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
    PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
    Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
    Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrinsic HER4/4ICD transcriptional activation domains are required for STAT5A activated gene expression.
    Han W; Sfondouris ME; Semmes EC; Meyer AM; Jones FE
    Gene; 2016 Oct; 592(1):221-226. PubMed ID: 27502417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation.
    Fujita Y; Yoshizumi M; Izawa Y; Ali N; Ohnishi H; Kanematsu Y; Ishizawa K; Tsuchiya K; Tamaki T
    Endocrinology; 2006 Mar; 147(3):1377-85. PubMed ID: 16322069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.
    Campbell MR; Amin D; Moasser MM
    Clin Cancer Res; 2010 Mar; 16(5):1373-83. PubMed ID: 20179223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathways: HER3 targeted therapy.
    Gala K; Chandarlapaty S
    Clin Cancer Res; 2014 Mar; 20(6):1410-6. PubMed ID: 24520092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
    Jacob W; James I; Hasmann M; Weisser M
    Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.
    Hellyer NJ; Cheng K; Koland JG
    Biochem J; 1998 Aug; 333 ( Pt 3)(Pt 3):757-63. PubMed ID: 9677338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators.
    Ikonen T; Palvimo JJ; Jänne OA
    J Biol Chem; 1997 Nov; 272(47):29821-8. PubMed ID: 9368054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two distinct nuclear receptor-interaction domains and CREB-binding protein-dependent transactivation function of activating signal cointegrator-2.
    Lee SK; Jung SY; Kim YS; Na SY; Lee YC; Lee JW
    Mol Endocrinol; 2001 Feb; 15(2):241-54. PubMed ID: 11158331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.
    Zhang Y; Opresko L; Shankaran H; Chrisler WB; Wiley HS; Resat H
    BMC Cell Biol; 2009 Oct; 10():78. PubMed ID: 19878579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.
    van Lengerich B; Agnew C; Puchner EM; Huang B; Jura N
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2836-E2845. PubMed ID: 28320942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment.
    Liu X; Liu S; Lyu H; Riker AI; Zhang Y; Liu B
    Biol Proced Online; 2019; 21():5. PubMed ID: 30930695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.